Role of lipid phosphate phosphatase 3 in human aortic endothelial cell function.
Lipid phosphate phosphatase 3; type 2 phosphatidic acid phosphatase β (LPP3; PPAP2B) is a transmembrane protein dephosphorylating and thereby terminating signalling of lipid substrates including lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P). Human LPP3 possesses a cell adhesion motif that allows interaction with integrins. A polymorphism (rs17114036) in PPAP2B is associated with coronary artery disease, which prompted us to investigate the possible role of LPP3 in human endothelial dysfunction, a condition promoting atherosclerosis.



To study the role of LPP3 in endothelial cells we used human primary aortic endothelial cells (HAECs) in which LPP3 was silenced or overexpressed using either wild type or mutated cDNA constructs. LPP3 silencing in HAECs enhanced secretion of inflammatory cytokines, leucocyte adhesion, cell survival, and migration and impaired angiogenesis, whereas wild-type LPP3 overexpression reversed these effects and induced apoptosis. We also demonstrated that LPP3 expression was negatively correlated with vascular endothelial growth factor expression. Mutations in either the catalytic or the arginine-glycine-aspartate (RGD) domains impaired endothelial cell function and pharmacological inhibition of S1P or LPA restored it. LPA was not secreted in HAECs under silencing or overexpressing LPP3. However, the intra- and extra-cellular levels of S1P tended to be correlated with LPP3 expression, indicating that S1P is probably degraded by LPP3.



We demonstrated that LPP3 is a negative regulator of inflammatory cytokines, leucocyte adhesion, cell survival, and migration in HAECs, suggesting a protective role of LPP3 against endothelial dysfunction in humans. Both the catalytic and the RGD functional domains were involved and S1P, but not LPA, might be the endogenous substrate of LPP3.
Sorbonne Universités, UPMC, INSERM UMR_S 1166, ICAN, Genomics and Pathophysiology of Cardiovascular Diseases Team, 91 Bd de l'Hôpital, 75013 Paris, France zahia.touat@upmc.fr ewa.ninio@upmc.fr.
Zahia
Z
Touat-Hamici
Sorbonne Universités, UPMC, INSERM UMR_S 1166, ICAN, Genomics and Pathophysiology of Cardiovascular Diseases Team, 91 Bd de l'Hôpital, 75013 Paris, France.
Henri
H
Weidmann
Department of Medicine/Division of Cardiology, University of California, Los Angeles, David Geffen School of Medicine, A2-237 Center for the Health Sciences, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1679, USA.
Yuna
Y
Blum
Sorbonne Universités, UPMC, INSERM UMR_S 1166, ICAN, Genomics and Pathophysiology of Cardiovascular Diseases Team, 91 Bd de l'Hôpital, 75013 Paris, France.
Carole
C
Proust
Sorbonne Universités, UPMC, INSERM UMR_S 1166, ICAN, Genomics and Pathophysiology of Cardiovascular Diseases Team, 91 Bd de l'Hôpital, 75013 Paris, France.
Hervé
H
Durand
Sorbonne Universités, UPMC, INSERM UMR_S 1166, ICAN, Genomics and Pathophysiology of Cardiovascular Diseases Team, 91 Bd de l'Hôpital, 75013 Paris, France.
Francesca
F
Iannacci
Sorbonne Universités, UPMC, INSERM UMR_S 1166, ICAN, Genomics and Pathophysiology of Cardiovascular Diseases Team, 91 Bd de l'Hôpital, 75013 Paris, France.
Veronica
V
Codoni
APHP, Hôpital de Bicêtre, Service de Biochimie, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France.|Université Paris Sud, UR Lip(Sys), UFR de Pharmacie, 5 rue Jean-Baptiste Clément, Châtenay-Malabry 92296, France.
Pauline
P
Gaignard
APHP, Hôpital de Bicêtre, Service de Biochimie, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France.|Université Paris Sud, UR Lip(Sys), UFR de Pharmacie, 5 rue Jean-Baptiste Clément, Châtenay-Malabry 92296, France.
Patrice
P
Thérond
Department of Medicine/Division of Cardiology, University of California, Los Angeles, David Geffen School of Medicine, A2-237 Center for the Health Sciences, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1679, USA.
Mete
M
Civelek
Sorbonne Universités, UPMC, INSERM UMR_S 933, Hôpital Armand-Trousseau, 4 rue de la Chine, 75020 Paris, France.
Sonia A
SA
Karabina
Department of Medicine/Division of Cardiology, University of California, Los Angeles, David Geffen School of Medicine, A2-237 Center for the Health Sciences, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1679, USA.
Aldons J
AJ
Lusis
Sorbonne Universités, UPMC, INSERM UMR_S 1166, ICAN, Genomics and Pathophysiology of Cardiovascular Diseases Team, 91 Bd de l'Hôpital, 75013 Paris, France.
François
F
Cambien
Sorbonne Universités, UPMC, INSERM UMR_S 1166, ICAN, Genomics and Pathophysiology of Cardiovascular Diseases Team, 91 Bd de l'Hôpital, 75013 Paris, France zahia.touat@upmc.fr ewa.ninio@upmc.fr.
Ewa
E
Ninio
D001011:Aorta / Q000201:enzymology*; D017209:Apoptosis; D020134:Catalytic Domain; D002448:Cell Adhesion; D002465:Cell Movement; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D042783:Endothelial Cells / Q000201:enzymology*; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D008246:Lysophospholipids / Q000378:metabolism; D009154:Mutation; D018919:Neovascularization, Physiologic; D010711:Phosphatidate Phosphatase / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D061251:Primary Cell Culture; D000072417:Protein Domains; D034622:RNA Interference; D015398:Signal Transduction; D013110:Sphingosine / Q000031:analogs & derivatives / Q000378:metabolism; D013379:Substrate Specificity; D014162:Transfection; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D016207:Cytokines; D018836:Inflammation Mediators; D008246:Lysophospholipids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C060506:sphingosine 1-phosphate; C521833:PLPP3 protein, human; D010711:Phosphatidate Phosphatase; D013110:Sphingosine; C032881:lysophosphatidic acid
Angiogenesis ; Apoptosis ; Atherosclerosis; Endothelial dysfunction
Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):837-45
24504738
Dev Cell. 2012 Sep 11;23(3):600-10
22975328
Biochim Biophys Acta. 2013 Jan;1831(1):74-85
22954454
J Biol Chem. 1998 Aug 21;273(34):22059-67
9705349
J Biol Chem. 1997 Sep 26;272(39):24572-8
9305923
Anticancer Res. 2010 Jul;30(7):2881-4
20683027
J Biol Chem. 1998 Jan 30;273(5):2910-6
9446602
PLoS One. 2012;7(7):e41834
22848628
Nat Genet. 2011 Mar 06;43(4):333-8
21378990
Nat Med. 2001 Dec;7(12 ):1291-7
11726968
J Biol Chem. 1999 Dec 10;274(50):35343-50
10585401
J Lipid Res. 2009 Apr;50 Suppl:S225-30
19066402
EMBO J. 2003 Apr 1;22(7):1539-54
12660161
J Biol Chem. 2004 Sep 24;279(39):41085-94
15280372
Cancer Cell. 2013 Jan 14;23(1):107-20
23273921
Biochem J. 2005 Oct 1;391(Pt 1):25-32
15960610
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14196-201
9826677
Physiol Rev. 2013 Jul;93(3):1317-542
23899566
Development. 2003 Oct;130(19):4623-37
12925589
J Lipid Res. 2013 Jul;54(7):1894-905
23667179
J Biochem. 2009 Dec;146(6):815-20
19692429
J Clin Invest. 2009 Jul;119(7):1871-9
19603543
Circ Res. 2001 Sep 14;89(6):496-502
11557736
J Clin Invest. 2000 Oct;106(8):951-61
11032855
Biochem J. 2006 Feb 1;393(Pt 3):657-68
16197369
J Biol Chem. 1996 Aug 2;271(31):18931-8
8702556
Cell Commun Signal. 2005 Aug 02;3:9
16076388
Biochim Biophys Acta. 2013 Jan;1831(1):126-32
22835522
Clin Cancer Res. 2009 Jan 15;15(2):492-501
19147754
Comp Biochem Physiol B Biochem Mol Biol. 2012 Sep;163(1):26-36
22613819
Circ Res. 2015 Jul 31;117(4):e41-53
26034042
Am J Hum Genet. 2010 Mar 12;86(3):399-410
20170901
PLoS Genet. 2015 Apr 02;11(4):e1005061
25835000
Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):52-9
23104851
Biochim Biophys Acta. 2002 May 23;1582(1-3):45-51
12069809
Int J Dev Biol. 2009;53(1):139-47
19123136
Nature. 2011 May 19;473(7347):298-307
21593862
Biochimie. 2011 Jan;93(1):61-70
20709140
Biochem J. 2002 Nov 1;367(Pt 3):751-60
12149127
Biochem Biophys Res Commun. 2008 Apr 18;368(4):852-7
18267109
J Biol Chem. 2001 Apr 20;276(16):13452-60
11278307
Biochim Biophys Acta. 2002 May 23;1582(1-3):33-44
12069808
FEBS Lett. 2003 Sep 25;552(2-3):240-6
14527693